Shopping Cart
Remove All
Your shopping cart is currently empty
Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $245 | In Stock | In Stock | |
| 5 mg | $647 | In Stock | In Stock | |
| 10 mg | $1,038 | - | In Stock | |
| 25 mg | $1,765 | - | In Stock | |
| 50 mg | $2,650 | - | In Stock |
| Description | Ocrelizumab (IDC-2403) is a humanized monoclonal antibody directed against CD20 for the treatment of multiple sclerosis. |
| In vivo | In a mouse model of multiple sclerosis, Ocrelizumab, administered subcutaneously or intravenously at a dose of 7.5 mg/kg once daily for 18 days, induced B-cell depletion by an antibody-dependent cellular cytotoxicity (ADCC) mechanism to inhibit lesions. In C57BL/6 mice, Ocrelizumab administered intravenously at a dose of 50 μg on days 7, 14, and 21 significantly reduced B and T cells in the blood, lymph nodes, and spleen.[1][2] |
| Synonyms | IDC-2403, IDC2403 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Molecular Weight | 145.5 kDa |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.